RT Journal Article SR Electronic T1 NMDA receptor antagonists and pain relief JF Neurology JO Neurology FD Lippincott Williams & Wilkins SP e1652 OP e1662 DO 10.1212/WNL.0000000000007238 VO 92 IS 14 A1 Thompson, Trevor A1 Whiter, Fiona A1 Gallop, Katy A1 Veronese, Nicola A1 Solmi, Marco A1 Newton, Paul A1 Stubbs, Brendon YR 2019 UL http://n.neurology.org/content/92/14/e1652.abstract AB Objective We conducted a meta-analysis of controlled trials that used experimental models of acute pain and hyperalgesia to examine the analgesic effects of NMDA receptor (NMDAR) antagonists.Methods Six major databases were systematically searched (to March 2018) for studies using human evoked pain models to compare NMDAR antagonists with no-intervention controls. Pain outcome data were analyzed with random-effects meta-analysis.Results Searches identified 70 eligible trials (n = 1,069). Meta-analysis found that low-dose ketamine (<1 mg/kg) produced a decrease in hyperalgesic area (standardized mean difference 0.54, 95% confidence interval [CI] 0.34, 0.74, p < 0.001) and a 1.2-point decrease (95% CI 0.88, 1.44, p < 0.001) in pain ratings from 4.6 to 3.4 on a 0–10 scale (a 26% reduction). Similar analgesia was observed for acute and hyperalgesic models and was constant across the dosing range (0.03–1.00 mg/kg). Moderate to high variability in effect size was observed and mild side effects (e.g., sedation, sensory disturbance) were common. No effects of dextromethorphan were found.Conclusions Findings provide robust evidence for analgesic and antihyperalgesic effects of ketamine, supporting its utility for acute and chronic pain management. However, pain relief was modest, suggesting ketamine may potentially be most useful when opioids are contraindicated, rapid analgesia is required, or for pain resistant to conventional medication.CI=confidence interval; NMDAR=NMDA receptor; RVE=robust variance estimation; SMD=standardized mean difference